Erschienen in:
01.04.2007 | Original Paper
Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma
verfasst von:
Shuichi Okada, Teruaki Hongo, Kimiyoshi Sakaguchi, Kazunori Suzuki, Shigeru Nishizawa, Takehiko Ohzeki
Erschienen in:
Child's Nervous System
|
Ausgabe 4/2007
Einloggen, um Zugang zu erhalten
Abstract
Objectives
The purpose of this study is to evaluate the stem cell mobilization capacity, anti-tumor effect, and feasibility of ifosfamide/carboplatin/etoposide (ICE) for transplant-eligible patients with medulloblastoma.
Materials and methods
Six patients (23 months to 18 years old) with high-risk or relapsed medulloblastoma received one cycle of ICE, which consisted of ifosfamide at 1.8 g/m2 for 5 days, carboplatin 400 mg/m2 for 2 days, and etoposide 100 mg/m2 for 5 days. Stem cells were mobilized with ICE followed by granulocyte colony-stimulating factor at 10 μg kg−1 day−1.
Results
After one cycle of ICE, the median number of harvested CD34+ cells per apheresis session was 11.85 × 106 cells/kg (range, 0.2 to 71.2 × 106 cells/kg). Two patients obtained a complete response and three patients a partial response. All patients experienced severe myelosuppression, and three infectious toxicities were observed.
Conclusions
These results suggest that ICE is optimal for mobilizing stem cells, effective for high-risk or relapsed medulloblastoma, and tolerable with limited non-hematological toxicity.